Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Non Peptidic αvβ3 Antagonists: Recent Developments

Author(s): Barbara Cacciari and Giampiero Spalluto

Volume 12 , Issue 1 , 2005

Page: [51 - 70] Pages: 20

DOI: 10.2174/0929867053363522

Price: $65

Abstract

The αvβ3 receptor, which are members of the group of the cellular adhesion molecules (CAM), are heterodimeric transmembrane glycoprotein receptors involved in processes such as cell-cell and cell-matrix adhesion, cell migration and signaling. Integrin αvβ3 receptor is expressed on almost all cells originating from the mesenchyme and seem to mediate several biological processes, including adhesion of osteoblasts to the bone matrix, migration of vascular smooth muscle cells, and angiogenesis. Many efforts were done in the last 10 years to individuate inhibitors for αvβ3 receptors, due to their involvement in important pathophysiological functions. In fact, selective αvβ3 antagonists offer new therapeutic opportunities for the treatment of several human pathologies like osteoporosis, restenosis and diseases involving neovascularization such as rheumatoid arthritis, tumor induced angiogenesis and metastasis. Purpose of this account is to summarize the recent developments in the field of non-peptidic αvβ3 antagonists.

Keywords: integrins, cellular adhesion molecules, crystal structure, vitronectin receptor, osteoblasts, carcinoma


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy